Neuland Laboratories reported a blockbuster performance for the fourth quarter ended March 2026, with sharp growth in revenue and profitability on a year-on-year basis.
The company posted consolidated net profit of ₹212.67 crore in Q4 FY26, registering a massive 664.7% YoY jump compared to ₹27.81 crore reported in the corresponding quarter last year.
Revenue from operations surged 136.3% YoY to ₹776.25 crore in Q4 FY26 versus ₹328.36 crore in Q4 FY25, driven by strong business momentum and higher operational performance.
Profit before tax (PBT) came in at ₹287.49 crore, up 631.6% YoY from ₹39.30 crore reported in the same quarter previous year.
For the full financial year FY26, the company reported revenue from operations of ₹2,022.99 crore compared to ₹1,476.84 crore in FY25, reflecting a growth of 37.0% YoY.
Annual net profit rose 39.9% YoY to ₹364.00 crore against ₹260.11 crore reported in the previous financial year.
The strong quarterly performance comes amid continued demand momentum in the pharmaceutical and API segments, helping the company deliver substantial margin expansion and earnings growth.